Evidence map›Paper›PMID 36997967›Full record

ArticleActa neuropathologica communications2023

Boosting neuregulin 1 type-III expression hastens SMA motor axon maturation.

Lingling Kong, Cera W Hassinan, Florian Gerstner, Jannik M Buettner, Jeffrey B Petigrow, David O Valdivia, Michelle H Chan-Cortés, Amy Mistri, Annie Cao, Scott Alan McGaugh and 6 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Persistent NRG1 Type III Overexpression in Spinal Motor Neurons Has No Therapeutic Effect on ALS-Related Pathology in SOD1Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Lingling Kong *Departments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0000-0002-6266-9741
Cera W Hassinan *Departments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0000-0003-1555-6987
Florian GerstnerCarl-Ludwig-Institute for Physiology, Leipzig University, Leipzig, Germany.
Jannik M BuettnerCarl-Ludwig-Institute for Physiology, Leipzig University, Leipzig, Germany.
Jeffrey B PetigrowDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0000-0002-3626-5161
David O ValdiviaDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0000-0002-0518-3171
Michelle H Chan-CortésDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0000-0003-1883-9317
Amy MistriDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.
Annie CaoDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.
Scott Alan McGaughDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.
Madeline DentonDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0000-0003-2924-4992
Stephen BrownDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0000-0002-1347-5908
Joshua RossDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA.ORCID 0009-0005-7149-6706
Markus H SchwabDepartment of Neuropathology, University Hospital Leipzig, Leipzig, Germany.
Christian M SimonCarl-Ludwig-Institute for Physiology, Leipzig University, Leipzig, Germany.ORCID 0000-0002-3996-4697
Charlotte J SumnerDepartments of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Rangos Building Room 234, Baltimore, MD, 21205, USA. csumner1@jhmi.edu.ORCID 0000-0001-5088-6012
Johns Hopkins University · USLeipzig University · DEUniversity Hospital Leipzig · DE

Funding

Translating Pathomechanisms into Treatment for Spinal Muscular AtrophiesR35NS122306 · NINDS · JOHNS HOPKINS UNIVERSITY · PI Charlotte Jane Sumner · 2021 to 2026
$6.3M
HopkinsPREP: Research, Community, Professional Training and Personal GrowthR25GM109441 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI WILSON, KATHERINE L · 2015 to 2024
$3.2M
NIGMS NIH HHS R25 GM109441NIH HHS R25 GM109441NIH HHS R35 NS122306NINDS NIH HHS R35 NS122306
6 · The paper itself

Abstract

Intercellular communication between axons and Schwann cells is critical for attaining the complex morphological steps necessary for axon maturation. In the early onset motor neuron disease spinal muscular atrophy (SMA), many motor axons are not ensheathed by Schwann cells nor grow sufficiently in radial diameter to become myelinated. These developmentally arrested motor axons are dysfunctional and vulnerable to rapid degeneration, limiting efficacy of current SMA therapeutics. We hypothesized that accelerating SMA motor axon maturation would improve their function and reduce disease features. A principle regulator of peripheral axon development is neuregulin 1 type III (NRG1-III). Expressed on axon surfaces, it interacts with Schwann cell receptors to mediate axon ensheathment and myelination. We examined NRG1 mRNA and protein expression levels in human and mouse SMA tissues and observed reduced expression in SMA spinal cord and in ventral, but not dorsal root axons. To determine the impact of neuronal NRG1-III overexpression on SMA motor axon development, we bred NRG1-III overexpressing mice to SMA∆7 mice. Neonatally, elevated NRG1-III expression increased SMA ventral root size as well as axon segregation, diameter, and myelination resulting in improved motor axon conduction velocities. NRG1-III was not able to prevent distal axonal degeneration nor improve axon electrophysiology, motor behavior, or survival of older mice. Together these findings demonstrate that early SMA motor axon developmental impairments can be ameliorated by a molecular strategy independent of SMN replacement providing hope for future SMA combinatorial therapeutic approaches.

Indexed as

Muscular Atrophy, SpinalNeuregulin-1AnimalsAxonsHumansMiceMotor NeuronsMyelin SheathNeuregulin-1Conduction velocityMotor axonNeuregulin 1 type III (NRG1-III)Neuromuscular junction (NMJ)Spinal muscular atrophy (SMA)

Identifiers

PMID36997967
PMCPMC10061791
OpenAlexW4361277533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.